SIC 2834 – Pharmaceutical Preparations
Valuation | |
---|---|
Market Cap ($M) | 45.26 |
Enterprise Value ($M) | -15.64 |
Book Value ($M) | 67.59 |
Book Value / Share | 1.41 |
Price / Book | 0.67 |
NCAV ($M) | 56.82 |
NCAV / Share | 1.19 |
Price / NCAV | 0.80 |
Profitability (mra) | |
---|---|
Return on Invested Capital (ROIC) | -1.00 |
Return on Assets (ROA) | -0.48 |
Return on Equity (ROE) | -0.55 |
Liquidity (mrq) | |
---|---|
Quick Ratio | 9.08 |
Current Ratio | 9.08 |
Balance Sheet (mrq) ($M) | |
---|---|
Current Assets | 66.40 |
Assets | 77.17 |
Liabilities | 9.58 |
Debt | n/a |
Equity | n/a |
Income Statement (mra) ($M) | |
---|---|
Revenue | 5.72 |
Operating Income | -80.57 |
Net Income | -75.41 |
Earnings Per Share Basic And Diluted | n/a |
Cash Flow Statement (mra) ($M) | |
---|---|
Cash From Operations | -60.52 |
Cash from Investing | -8.51 |
Cash from Financing | 0.79 |
(click for more detail) |
File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
---|---|---|---|---|
13G/A | Adage Capital Partners Gp, L.l.c. | 9.79 | 81.36 | |
13D/A | Redmile Group, LLC | 11.80 | -0.70 | |
13G/A | Prosight Management, LP | 14.00 | 24.49 | |
13G/A | Vanguard Group Inc | 5.03 | 0.00 | |
13G | BlackRock, Inc. | 5.50 | 0.00 | |
13G/A | Fmr Llc | 0.28 | -98.10 |
Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
---|---|---|---|---|
(click for more detail) |
Date | Insider Trades | Code | Shares | Value |
---|---|---|---|---|
(click for more detail) |
Short Volume | |||
---|---|---|---|
Market Date | Short Volume | Total Volume | Short Volume Ratio |
9,845 | 64,577 | 15.25 | |
9,119 | 61,337 | 14.87 | |
14,589 | 52,115 | 27.99 | |
13,087 | 66,806 | 19.59 | |
26,210 | 82,194 | 31.89 | |
(click for more detail) |
Similar Companies | |
---|---|
SRPT – Sarepta Therapeutics, Inc. | SRRK – Scholar Rock Holding Corporation |
STOK – Stoke Therapeutics, Inc. | SVRA – Savara Inc. |
SWTX – SpringWorks Therapeutics, Inc. |
Financial data and stock pages provided by
Fintel.io